機関投資家はアブビー株を押し上げ 業績が好調で 予想値が上昇したことで "適度な買い"の評価を上げました Institutional investors boosted AbbVie shares as strong earnings and raised guidance fueled a "Moderate Buy" rating.

機関投資家はAbbVie Inc.の株式を増加させ,Nicholas Wealth LLC,Stonebrook Private Inc.とTraub Capital Management LLCは第2四半期に株式を追加しました. Institutional investors increased their stake in AbbVie Inc., with Nicholas Wealth LLC, Stonebrook Private Inc., and Traub Capital Management LLC all adding shares in the second quarter. 同社は,0.09ドルで予想を上回る1.86ドルのEPSの強いQ3利益を報告し,売上高は前年比9.1%増加して15780億ドルとなった. The company reported strong Q3 earnings of $1.86 EPS, beating estimates by $0.09, and revenue rose 9.1% year-over-year to $15.78 billion. AbbVieは2025年度のEPSガイドブックを3.3-3.3.3に上げ,四半期の配当額を1.73ドルに増額し,3%を上回る. AbbVie raised its full-year 2025 EPS guidance to $3.320–3.360 and increased its quarterly dividend to $1.73, yielding 3.0%. 株式は413.27億円の市場キャップで233.83ドルを取引しているが,同社は"モデレート・バイヤー"の評価と240.14ドルの目標価格について合意している. The stock, trading at $233.83 with a market cap of $413.27 billion, has a consensus "Moderate Buy" rating and a target price of $240.14.